DFTX Stock Price Today (November 2026) — Definium Therapeutics, Inc. Analysis & Key Metrics 2026-11-06
Definium Therapeutics, Inc. (DFTX) is trading at $33.27, up 9.59% today (as of November 2026).The stock is trading below its 50-day moving average but at or above its 200-day moving average.
- According to consensus analyst estimates, the 1-year price target is $72.56 (118.1% upside).
- Volatility is high (75.21% annualized), above 40%.
- From the latest financial filings: Debt is 0.04 times shareholders' equity.
DFTX Stock Analysis: Key Metrics & Valuation (November 2026)
Key figures from the latest data
Definium Therapeutics, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $3.42B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Latest quarter vs year ago
Analyst Target
+118.1% upside potential
Key Investor Questions About DFTX
What the latest data shows
DFTX is trading below its 50-day moving average but at or above its 200-day moving average, and its RSI of 44.2 is in the neutral zone (between 30 and 70).
- Technicals: Neutral (RSI 44.24) (Mixed: below 50-day, above 200-day average)
- Fundamentals: Debt/equity 0.04x
- Total debt is $36.47M (0.04 times equity).
- 30-day volatility is 75.21% annualized, which counts as high (above 40%).
52-Week Trading Range
Over the past year, DFTX stock traded between $10.47 and $49.70 and currently trades in the middle of that range.
Volatility & Risk Profile
30-day volatility is 75.21% annualized, which counts as high (above 40%). Beta 1.31: the stock has moved much more than the market.
Institutional & Insider Ownership
Institutions own 96.39% of the shares, and short interest is 7.52% of the float.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Definium Therapeutics to Participate at Upcoming Investor Conferences
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value
Latest TickZen Insights
All insights →No TickZen article on DFTX yet. Our newest analysis:
Explore More Analysis for DFTX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 9, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (DFTX) is currently trading at $33.27. The RSI (14-day) is 44.2, in the neutral zone (between 30 and 70). Wall Street analysts have a consensus "Strong Buy" recommendation. The mean analyst price target of $72.56 implies 118.1% upside from current levels. 30-day volatility is 75.21% annualized, which counts as high (above 40%).
Based on current valuation metrics for Definium Therapeutics, Inc. (DFTX): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 4.87. Different industries trade at different multiples, so these figures are most useful next to Biotechnology peers.
Based on 18 analysts covering DFTX, the consensus price target is $72.56. This represents a 118.1% upside from the current price of $33.27. The range spans from a low target of $55.00 to a high target of $91.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Strong Buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Definium Therapeutics, Inc. (DFTX) does not currently pay a regular dividend.
Key risks for Definium Therapeutics, Inc. (DFTX) shown in the latest data: 1. High volatility (75.2% annualized, above 40%). 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Moves in the broader stock market (Beta 1.31: the stock has moved much more than the market).
Here is Definium Therapeutics, Inc.'s (DFTX) current debt and financial health profile: Total debt stands at $36.47M. The debt-to-equity ratio is 0.04x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.95, indicating strong short-term liquidity. The quick ratio is 6.90. The company holds $1.08B in cash and equivalents. Free cash flow is negative at -$167.95M, which could limit the company's ability to manage debt obligations.